Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Chronic Myeloid Leukemia

Clinical and regulatory intelligence for Chronic Myeloid Leukemia with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
0
Assets
2

Relevant assets

Asciminib →
Feasibility →

Relevant companies

Novartis →

Recent signals(3)

ClinicalAugust 13, 2026

Feasibility Study on Digital Tool for Chronic Myeloid Leukemia Patient Monitoring

Versailles Hospital is conducting a feasibility study to evaluate a digital monitoring tool for chronic myeloid leukemia patients who have discontinued treatment for up to 2 years. The study will assess the tool's usage rates over a 12-month period, with a threshold of 60% for feasibility.

ClinicalAugust 1, 2026

Asciminib Efficacy in Real-World CML Patients in Second-Line Treatment Assessed

An observational study is underway to evaluate the efficacy and tolerability of asciminib in real-world settings for CML patients in second or subsequent lines of treatment.

ClinicalJuly 1, 2026

Novartis initiates pediatric study for asciminib in Chronic Myeloid Leukemia

Novartis is conducting a study to evaluate the dose and safety of asciminib in pediatric patients with Chronic Myeloid Leukemia.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Chronic Myeloid Leukemia →
Hematology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.